Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
-1.29%-3.91%+51.98%+69.06% 65.56B
-2.94%-1.43%+7.50%+88.33% 60.41B
-0.97%+0.48%+23.14%+87.10% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
+0.23%+2.14%+14.85%+46.22% 36.7B
-3.15%-16.63%+146.30%+685.27% 36.09B
-2.14%-3.46%+74.99%+55.93% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -0.46%-1.64%+34.98%+175.71% 45B
Weighted average by Cap. -1.27%-1.58%+34.37%+149.74%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-